Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10885861 | 0.86 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL4707157 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL16847676 | 0.84 | CTSK (0.52) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL3497561 | 0.84 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL4442846 | 0.83 | KMT2A (0.60) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL3565164 | 0.82 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL30898810 | 0.82 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL20382395 | 0.82 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL19797962 | 0.82 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNACA12 | |
| SCHEMBL10350695 | 0.82 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | claimed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3106464-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106464-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2861594-B1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-08-24 | — | — | EP | disclosed |
| EP-2861594-B1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-06-30 | — | — | US | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102304096-A | CETP inhibitors | MERCK SHARP & DOHME | 2012-01-04 | — | — | CN | disclosed |
| WO-2010146881-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | 株式会社デ・ウエスタン・セラピテクス研究所 (JP) | 2010-12-23 | — | — | WO | disclosed |
| CN-101365689-A | 1,3-oxazolidin-2-one derivatives useful as cetp inhibitors | MERCK & CO INC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-0259835-B1 | PYRIDAZINONE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4843072-A | Antihypertensive pyridazinone aminoisopropanol derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4760061-A | Antioestrogenic agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | disclosed |
| EP-0259835-A2 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0160508-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, KCNN2 | MEN1 2312/4885KMT2A 3766/4885SMN1; SMN2 549/4885 |
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | MEN1 4055/4885KMT2A 3678/4885SMN1; SMN2 281/4885 |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | MEN1 1128/4885KMT2A 3143/4885SMN1; SMN2 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.